title: Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome.
abstract: BACKGROUND
  Vogt-Koyanagi-Harada (VKH) syndrome is characterized by bilateral diffuse uveitis associated with auditory, neurological, and cutaneous signs and symptoms. VKH syndrome is a cell-mediated autoimmune disease against melanocytes. Choroidal neovascularization (CNV) occurs in 15% of VKH patients and is associated with poor visual prognosis.
  
  
  METHODS
  We report on two patients with VKH syndrome and CNV that were treated with intravitreal bevacizumab.
  
  
  METHODS
  One of the VKH patients also had an extrafoveal CNV membrane and underwent multiple intravitreal injections of bevacizumab in combination with laser photocoagulation, with subsequent improvement in visual acuity. The second had a subfoveal CNV that responded to a single intravitreal injection of bevacizumab.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab may be a useful drug to treat CNV in eyes with VKH syndrome.
authors.affiliation: Instituto de Cirugía Ocular, San José, Costa Rica. LW65@cornell.edu.|, Apdo 144-1225 Plaza Mayor, San José, Costa Rica. LW65@cornell.edu.
authors.forename: Lihteh
authors.initials: L
authors.lastname: Wu
authors.affiliation: Instituto de Cirugía Ocular, San José, Costa Rica.
authors.forename: Teodoro
authors.initials: T
authors.lastname: Evans
authors.affiliation: Hospital Universitario Austral, Buenos Aires, Argentina.
authors.forename: Mario
authors.initials: M
authors.lastname: Saravia
authors.affiliation: Servicio de Oftalmologia, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors.forename: Ariel
authors.initials: A
authors.lastname: Schlaen
authors.affiliation: Servicio de Oftalmologia, Hospital de Clinicas Jose de San Martin, Universidad de Buenos Aires, Buenos Aires, Argentina.
authors.forename: Cristobal
authors.initials: C
authors.lastname: Couto
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D041623:Tomography, Optical Coherence; D014607:Uveomeningoencephalitic Syndrome / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab